Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives

B. Ten Haaft(University of Amsterdam), Ángela Lamarca(Hospital Universitario Fundación Jiménez Díaz), Víctor Moreno, Manuel Pedregal(Hospital Universitario Fundación Jiménez Díaz), Heinz‐Josef Klümpen(University Medical Center Groningen), J Prato(Hospital Universitario Fundación Jiménez Díaz)
European Journal of Cancer
January 19, 2024
10.1016/j.ejca.2024.113564
Cited by 50

Related Papers

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1k
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
|The Lancet Oncology|2021|741
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|502